pharmaphorum3d
Switch study says patients prefer ViiV’s injectable HIV drug
ViiV – which is majority-owned by GSK – has said Cabenuva is central to its plans to grow its HIV sales over the next five years alongside long-acting injectable Apretude (cabotegravir), an ...
pharmaphorum6d
Record Shingrix sales help GSK raise 2022 forecasts
and a contribution by recently-launched long-acting injectable Cabenuva (cabotegravir). On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £ ...
FiercePharma19d
Argenx's Vyvgart tops Trinity’s latest launch success analysis, beating out several Big Pharma debuts
That equation led Vyvgart, argenx’s treatment for generalized myasthenia gravis (gMG), to take the top spot, with an overall score of 3.9. Cabenuva, GSK’s long-acting HIV treatment ...
Pharm Exec18d
Real-World Data Demonstrates Efficacy of Apretude and Cabenuva in HIV Prevention, Treatment
New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and treatment, with Apretude showing zero HIV acquisitions and Cabenuva ...
Zacks.com on MSN24d
Glaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue?
HIV sales rose 14% driven by strong demand and increased market share for oral two-drug regimens, Dovato and Juluca, and long-acting regimens like Cabenuva and Apretude. GSK generates the majority ...
Business Wire19d
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
About Cabenuva (cabotegravir + rilpivirine ... is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in ...
Yahoo Finance19d
ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP
LONDON, March 12, 2025--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer ... data were also presented for Cabenuva, the only approved ...